Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Triethylamine | HCID 8471 | — |
| Reactant | Cyclopropylamine | HCID 69828 | — |
| Reactant | Triphosgene | HCID 94429 | — |
| Reactant | HCID 66589022 | HCID 66589022 | — |
| Solvent | Dichloromethane | HCID 6344 | — |
| Product | HCID 57424539 | HCID 57424539 | — |
Reaction Steps
A solution of 4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)aniline (47 mg, 0.097 mmol) in dichloromethane (3 mL) was treated with triethylamine (0.13 mL), followed by triphosgene (14 mg, 0.048 mmol). After the passage of five minutes, cyclopropylamine (0.14 mL) was added. The mixture was concentrated to dryness under reduced pressure. The resultant residue was purified via reverse-phase high performance liquid chromatography using a Phenomenex Gemini 21 mm×100 mm column, running a gradient elution of 10% acetonitrile/90% of 0.1% aqueous trifluoroacetic acid to 75% acetonitrile over 30 minutes. After the concentration of fractions under reduced pressure, 1-cyclopropyl-3-(4-{4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl}phenyl)urea (67 mg) was obtained. MS (ES+): 571.5, 572.5 (M+H)+
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08129371B2 |
|---|
| Source dataset | uspto-grants-2012_03 |
|---|
| ORD ID | ord-bd30d534c1b743c7acaf28f57f282d6c |
|---|
| Source note | uspto-grants-2012_03 |
|---|